david-sans-david-sans-is-reporting-systems-to-the-ceo-and-the-board-of-directors-and-as-ma
david-sans-served-as-vp-of-finance-and-investment-strategy-at-imclone.jpg
david-sans-david-sans-completed-mba-at-the-eth-in-zurich-and-a-board-certification-in-cell

David Sans

About Me

A Chemical Engineer by training, David Sans holds a PhD in Chemometrics and Artificial Intelligence from the labs of Dr. Stoessel at the ETH in Zurich, as well as a Board Certification in Cell Therapies from Mount Sinai Medical Center. David holds FINRA Series 7, 63, 15, and 55 licenses, making him a fully qualified Healthcare Investment Banking professional. David has more than 12 years of experience in Healthcare Investment Banking, where he has provided a full range of investment banking advisory services, including mergers and acquisitions, project finance, capital raising, and special circumstance consulting services. The Healthcare Investment Banking transactions conducted by David's clients have totaled over 100 since 2008. David's clients include financial institutions, health-care institutional investors, and strategic partners. The AI Pathology platform at Mount Sinai Hospital in New York City, which David developed and sold to Philips Corporation in 2021, is one example of David's work. Among David's initial public offerings (IPOs) is Annovis Bio, which is expected to generate $600 million in value from its $10 million IPO in December 2020. As Vice President of Finance and Investment Strategy at ImClone Systems, David reported to the CEO and the Board of Directors, and as Managing Director of Healthcare Banking at ThinkEquity, David gained extensive experience in the healthcare industry. When Glivec® (Imatinib) was first introduced in Switzerland, David worked as a Sr. Medical Scientist at Novartis. Later, he worked as Director of Market Analytics at Pfizer with the introduction of Rebif® (interferon beta-1a for multiple sclerosis) and Macugen.